Allo-CBSCT (cord blood stem cell transplant) has been applied in six adult patients with severe aplastic anemia (SAA). Anti-lymphocyte globulin (ALG) 40 mg kg À1 d À1 Â 3 days combined with cyclophosphamide (CTX) 20 mg kg À1 d À1 Â 3 days constituted a lower intensive conditioning regimen. The prophylaxis of GVHD consisted of standard CsA and MTX. Patients are all male having a mean age of 26.5 years (range 22-38), and a median weight of 55.6 kg (range 52-60 kg). Cord blood searches were all conducted at Guangzhou Cord Blood Bank. Three of six patients in our study received one unit of cord blood in a procedure, whereas for another three patients, two units of cord blood (double units) were infused at the same time in a transplant protocol. The nine units of umbilical cord blood (UCB) infused contained 1.6-10.7 Â 10 7 nucleated cells/kg body weight of the recipient after thawing. HLA antigens were identical in one unit, 1 antigen mismatched in seven, 2 antigens mismatched in 1. As of February 2003, after a median follow up of 20 months (range 7-50), four patients are alive and disease free. Five patients engrafted with molecular biology analyses showing donor-recipient mixed chimerism post transplant which is stable and persistent. One patient died of severe infection in the third month from transplant and another patient died in the early stage post transplant of serious aspergillus infection without evidence of engraftment.
tion; severe aplastic anemia BMT remains the first choice in children and young adults with SAA. Full matched sibling BMT may also considered in older patients if there is no response to the first-line therapy with immunosuppressive agents. 1 For patients without a sibling donor having no response to one or more courses of immunosuppressive therapy a fully matched unrelated donor BMT should be considered as alternative salvage therapy. Finding related or unrelated individuals who are HLA-identical to some patients, however, is difficult and time consuming because of the extreme polymorphism of most HLA loci. Umbilical cord blood is another alternative sources of stem cells that improves donor availability for transplantation because frozen and stored UCB can be made available on demand. Infectious agents, particularly cytomegalovirus (CMV), are rarely seen in the new born than in adults. Furthermore, UCBT may have a lower incidence and severity of GVHD than conventional BMT, allowing successful transplantation in the HLAmismatched recipient. Recently, investigators have explored the applicability of UCB stem cells as a rescue therapy for both malignant and non-malignant hematological diseases with some promising results. 2, 3 We first reported in 2000 an UCB transplantation from unrelated donor in an adult with SAA 4 and now report additional experience.
Patients and methods

Patients
Six adult patients with SAA on our study received allo-CBSCT from December 1998 to January 2002. All patients had previously failed immunosuppressive therapy and had no HLA-matched sibling donor. They were all male with the average age of 26.5(22-38) at the time of transplant. Mean interval from diagnosis to CBSCT was 4.6 months (range 2-10 months) and all remained transfusion-dependent when transplanted. All patients were transfused before transplant and all but one had more than four transfusions. Bone marrow smears and biopsy showed failure of hematopoiesis and increased nonhematopoietic cells and fat cells. Hemolytic screening tests were negative for acidified-serum hemolysis, sucrose lysis test and venom hemolysis test. In all patients, severe aplastic anemia was diagnosed by standard criteria 5 with the exclusion of MDS.
Umbilical cord blood
UCBs were found in Guangzhou cord blood bank. They were collected after delivery and cryopreserved in 10% DMSO in a programmed cell freezer to avoid cell loss which might impair engraftment. Syphilis and viral tests including HIV, hepatitis B and C and CMV were performed on both mothers' blood and cord blood units. Tests for genetic diseases such as thalassemia were also performed. Each cord blood was kept in liquid nitrogen below À1921C. Trypan blue test to determine the viable cell frequency, flow cytometry to count CD34 þ cells and cell culture for CFU-GM were done immediately after the cells were thawed. UCBs recovery rate were 79-93.5% after thawing. All UCBs and related patients data were listed in Table 1 .
Preparative conditioning regimen
Patients in our study received a pretransplant regimen of both CTX 20 mg/kg/day i.v. on days -6, -5, -4, and ALG 40 mg kg À1 day À1 i.v. on days -3, -2, -1. CTX was given daily as a 2 h infusion. Mesna was administered for uroprotection before the first dose of CTX to 24 h after the last dose of CTX. ALG was given daily by continuous i.v. infusion over 6 h.
GVHD prophylaxis
All patients received GVHD prophylaxis consisting of CsA 4 mg/kg/day (days 1-5) followed by regulated dosage according to blood CsA level and MTX 15 mg/m 2 (day 1) and 12 mg/m 2 (days 3, 6, 11). They also received methyprednisolone 1.0 mg kg À1 day À1 p.o. from day 1 to 14, 0.5 mg kg À1 day À1 from day 15 to day 28.
Supportive care
Prophylaxis of infections included acyclovir, fluconazole, ofloxacin, metronidazole and SMZ. CMV-seropositive patients (patients 1, 2, and 5) received prophylactic ganciclovir. All blood products were irradiated and filtered.
Red blood cell and platelet transfusions were performed to maintain a hemoglobin of 470g/l, platelet count 420 Â 10 9 /l. Patients were given a combination of G-CSF 5 ug kg À1 day À1 and EPO 6000 IU every other day from day 0 until recovery from aplasia. All patients received intravenous immunoglobulin prophylaxis and hyperalimentation when needed.
Assessment of engraftment
Hematopoietic chimerism was evaluated by cytogenetic methods as microsatellite DNA fingerprinting for detection of multiple short tandem repeat loci. The DNA samples were extracted from bone marrow and /or peripheral white blood cells. ABO-mismatched pairs were usually tested to find conversion of the blood group.
The immunoreconstitution evaluation was carried out prior to and 1, 2, 3, 6, 9, 12 months after transplantation Table 1 Characteristics of patients, donors, and cord blood data after thawing 
Results
Engraftment and outcome
Evidence Table 2 . These four patients have become transfusion-independent and achieved hematopoietic reconstitution after the transplant. The bone marrow aspirates had demonstrated hematopoietic aplasia until 2, 4, 2.5, and 3 months post transplant and showed complete recovery of hematopoiesis for 13.5, 16, 17, and 18.5 months observed from the transplant in patients 1, 2, 4, and 5, respectively.
NK cell activity generally recovered around 50 days post transplant. Absolute lymphocyte count, B-lymphocytes, T-lymphocytes recovered to normal levels after 6 months. CD4 þ T-lymphocytes were decreased significantly during the first 150 days posttransplant while Umbilical cord blood transplant for adult patients P Mao et al
Donor -recipient chimerism
Repeated DNA amplification and microsatellite DNA fingerprinting showed persistent stable chimerism in those four patients (patients 1, 2, 4, and 5). The study of patient 1 for a long period has demonstrated a stable mixed chimerism post transplant (Figure 1 ). The chimerism analyses of peripheral blood and bone marrow in patient 2 revealed 40% and 42% donor hematopoiesis 3 and 12 months after transplant, respectively (Figure 2) . In patients (patients 4 and 5) receiving two units of cord blood, only a single unit engrafted in each of them (Figure 3) . DNA of the donor cells first appeared in bone marrow and/or peripheral blood samples in these two patients around day þ 20, when the leukocyte count was just above 1.0 Â 10 9 /L. Thereafter, and from a few days before the leukocyte count increased to around 3.0 Â 10 9 /L, donor cells were obviously demonstrated in the recipients by short tandem repeat loci detection and a stable mixed chimerism with 30-40% donor hematopoiesis has long been observed. In another patient (patient No. 6) who received two units, no evidence of engraftment of either unit was found. ABO blood group changed from host origin into donor type in two patients (patients 2 and 5) developing 2 and 2.5 months post transplant respectively.
GVHD
Chronic GVHD was diagnosed in two patients limited to the skin, developing after withdrawal of CsA. Localized erythematous plaques and papules were manifested. The skin biopsy demonstrated a subcutaneous infiltration by lymphocytes. No treatment has been undertaken for this mild cGVHD that has been persistent but has not progressed. There has been no evidence of GVHD in the gut or in the liver.
Discussion
Umbilical cord blood has recently emerged as an alternative source of hematopoietic stem cells especially for those patients lacking an HLA-matched related donor. Cord blood can be collected and stored on a large scale, has no risk to donors, a lower risk of GVHD and the ability to reconstitute hematopoiesis and immunity after transplant. UCB contains a significantly higher number of early and committed progenitor cells and now is widely used in patients with malignant and non-malignant hematological diseases. UCBT mainly remains applied to children because of the limited number of hematopoietic cells, raising the question of whether it can reconstitute adult patients. Umbilical cord blood stem cell transplantation has been successfully employed in our study for an adult patient with SAA since 1998. 6 The patient remained in a complete hematopoietic recovery for 50 months. Cytogenetic evidence showed long term stable donor-recipient chimerism. UCB transplant has been performed for additional SAA adult patients thereafter and the similar successful engraftment of UCB cells could be reproduced. Gluckman 7 indicated that neutrophil recovery was 76% in patients receiving 41.0 Â 10 7 NC/kg in UCBT including some adult patients. Kai 8 reported six adults with leukemia receiving UCBT and all the patients had full chimerism. We report here durable donor-recipient mixed chimerism can be achieved by unrelated UCBT in adult patients with SAA, suggesting again that UCB could be employed as a source of hematopoietic stem cell for adult transplantation.
In our study durable and stable donor-recipient mixed chimerism was formed after transplant to provide a platform at which the immunotolerance may be created between the cells of donor and recipient. Patients are usually prepared for transplantation with cyclophosphamide of total dose 200 mg /kg, 9 whilst in our group, only one third of that dose was used in the preparative conditioning regimen. The combination of ALG and CTX we use is enough to suppress the T-lymphocytes of the host and to facilitate engraftment of UCB cells producing stable donor-recipient mixed chimerism. This regimen may also reduce transplantation related toxicity.
We transplanted SAA patients with UCB units mismatched with the recipient for 1 (n ¼ 2) or 2 HLA loci (n ¼ 1). Cell dose was the most important factor for engraftment and survival. 10, 11 Double chimeras created by UCBT from two partially matched unrelated donors have been recently reported. 12 Two units of UCB cells transplanted into a recipient may increase the cell dose to support reconstitution of hematopoiesis especially in the early stage of transplant. We have two patients receiving double units of UCBT but resulting in engraftment of only one unit. It remains unclear whether double unit transplantation has the advantage of increasing engraftment over one unit.
We summarize that unrelated umbilical cord blood could be employed as a source of hematopoietic stem cell for adult patients with SAA. Our ALG and CTX based conditioning regimen proves effective, well tolerated, less toxic, and safe. The following use of immunosuppressive agents like CsA may also exert a therapeutic effect in addition to transplant.
